AnaBios Corporation

AnaBios is proud to announce its collaboration with Arena Pharmaceuticals, Inc. and Pfizer in co-authoring a significant research paper on Etrasimod, recently approved for the treatment of ulcerative colitis. This joint effort highlights the commitment of all parties to advancing scientific knowledge and innovation in the field. The paper can be accessed below. #drugdiscovery #earlyhumaninsights

Scientists from the The National Institutes of Health and AnaBios recently published a new paper that identifies two distinct populations of #nociceptive neurons in humans, one of which responds to mu-opioids such as morphine while the other set of nociceptors does not respond. This discovery advances our understanding of where and how opioids modulate the neurons that transmit pain signals. This research provides a crucial framework for developing targeted pain treatments that reduce reliance on opioids as well potentially developing more effective and safer alternatives to current opioid medications. Click below to read the full paper. #earlyhumaninsights #drugdiscovery

Researchers from Columbia University and AnaBios recently published a paper in Nature Communications that features a new class of iboga alkaloids called oxa-iboga, which could revolutionize the treatment of #opioid addiction. Unlike traditional ibogaine and noribogaine, these compounds do not pose #cardiacsafety risks and show superior efficacy in animal models of opioid use disorder. Oxa-iboga compounds were tested on primary human #cardiomyocytes, showing no pro-arrhythmic risk and reduced negative inotropic effects. They induce long-lasting suppression of morphine, heroin, and fentanyl intake after a single dose or short treatment, reverse opioid-induced hyperalgesia, and suppress opioid-seeking behavior in rodent models. These compounds offer a promising, mechanistically distinct approach to treating opioid use disorder, potentially reducing the risks and complexities associated with current treatments. #drugdiscovery #earlyhumaninsights #naturecommunications

Learn more about AnaBios Hepatocyte Media, a suite of specialized media designed to optimize the growth, maintenance and functionality of human hepatocytes, in our latest video. Learn about the role of protective agents, osmolytes and nutrients in maintaining cell viability during the thawing process, as well as how our specifically-formulated culture medium is designed to support the attachment and initial growth of #hepatocytes. #drugdiscovery #earlyhumaninsights #liverresearch

AnaBios is pleased to announce that Dr. David W. Salzman, Gatehouse Bio Chief Executive Officer, is the winner of the 2024 Translational Research Grant Award. Dr. Salzman will obtain up to $15,000 in AnaBios’ high-quality precision-cut lung slices to help Gatehouse Bio advance #drugdevelopment in idiopathic pulmonary #fibrosis. Click the link below to read the full announcement. #earlyhumaninsights #translationalresearch

The deadline to submit an abstract for our Translational Research Grant is next week! One winning researcher will be awarded $15K in tissue samples to utilize in their #translationalresearch project. To view grant rules and apply, visit our website today. #earlyhumaninsights #drugdiscovery #painresearch #cardiacresearch

AnaBios is proud to contribute to a groundbreaking study on the use of Cyclin A2 (CCNA2) to induce cardiac repair. Researchers have shown that CCNA2 gene delivery can induce complete cytokinesis in isolated adult human #cardiomyocytes, paving the way for the development of a new cardiac regenerative therapy. This innovative approach has the potential to revolutionize the treatment of heart disease. #cardiacregeneration #stemcells #earlyhumaninsights #drugdiscovery

The deadline to submit an abstract for our Translational Research Grant is less than 2 weeks away. The winning researcher will receive $15K in human tissue samples to use towards their #translationalresearch project. To view rules and submit your abstract, visit our website. #earlyhumaninsights #drugdiscovery #painresearch #cardiacresearch

Unlock the power of human biology with AnaBios' precision cut lung slices. Our groundbreaking technology offers a superior alternative to traditional preclinical models, delivering unparalleled predictive accuracy for your respiratory #drugdiscovery programs. Unlike conventional methods, our proprietary process halts ischemic breakdown, ensuring #lungtissue samples maintain their native, in vivo-like characteristics. This innovative approach provides researchers with high-quality human lung slices that faithfully recapitulate the physiological environment. Contact us to learn more. #earlyhumaninsights #PCLS #lungresearch

We're still accepting abstract submissions for the 4th Annual AnaBios Translational Research Grant. The winning scientist will receive $15,000 in tissue samples to help with their translational research project. The deadline to apply is June 30. Learn more about submission guidelines on our website. #TranslationalResearch #DrugDiscovery #HeartResearch #PainResearch #Toxicology